Sheet 1 of 6 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. ATENT AND TRADEMARK OFFICE 4172-3 09/678,202 INFORMATION DISCLOSURE STATEMENT **APPLICANT** BAR-OR et al. (Use several sheets if necessary) FILING DATE **GROUP ART** September 29, 2000

## **U.S. PATENT DOCUMENTS**

	7	·				1	
*EXAMINER INITIAL		DOCUMENT NÚMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP:
	1	A',025,499	5/24/77	Thomas	260	112.5	
	*2	,4′,461,724	7/24/84	Konishi	260	112.5	
	3	4,591,648	5/27/86	Jones et al.	548	344	
	*4	4,665,054	5/12/87	Pickart	514	18	
	5	4,684,624	8/4/87	Hosobuchi et al.	514	15	
	6	4,746,649	5/24/88	Raddatz et al.	514	18	
	*7	4,760,051	7/26/88	Pickart	514	6	
1)	*8	4,767,753	8/30/88	Pickart	514	18	
00	<b>*</b> 9	4,810,693	3/7/89	Pickart	514	18	
XX	*10	4,877,770	10/31/89	Pickart	514	18	
	11	4,912,118	3/27/90	Hider et al.	514	332	
	*12	5,023,237	6/11/91	Pickart	514	18	
	*13	5,059,588	10/22/91	Pickart	514	12	
	14	- 5,087,696	2/11/92	Parker et al.	540	465	
1)	15	5,101,041	3/31/92	Troutner et al.	548	518	
$\bigcap$	16	5,104,865	4/14/92	Hider et al.	514	188	
JA .	*17	5,118,665	6/2/92	Pickart	514	6	
1	*18	5,120,831	6/9/92	Pickart	530	331	
	*19	5,135,913	8/4/92	Pickart	514	16	-
1,	*20	5,145,838	9/8/92	Pickart	514	18	
V	*21	5,164,367	11/17/92	Pickart	514	6	
00	*22	5,177,061	1/5/93	Pickart	514	18	
	23	5,214,032	5/25/93	Pickart	514	16	
	24	5,227,307	7/13/93	Bar-Or et al.	436	63	
	25	5,290,519	3/1/94	Bar-Or et al.	522	61	
	26	5,252,559	10/12/93	Kronholm et al.	514	18	
	*27	5,348,943	9/20/94	Pickart	514	18	
11/	28	5,380,747	1/10/95	Medford et al.	514	423	
XX	29	5,382,431	1/17/95	Pickart	424	401	

	Q X		
EXAMINER Saud	Lellan	DATE CONSIDERED /D/	6/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-14497 AND TRADEMARK OFFICE . DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO. 4172-3

SERIAL NO. 09/678,202

**APPLICANT** 

BAR-OR et al.

FILING DATE September 29, 2000 **GROUP ART** 

00							
25/	30	5,422,096	6/6/95	Lauffer et al.	424	9.363	
1	31	5,455,229	10/3/95	Hahn et al.	514	18	
	32	5,470,876	11/28/95	Proctor	514	492	,
	33	5,476,939	12/19/95	Johnson	546	141	
	34	5,503,987	4/2/96	Wagner et al.	435	7.94	
V	35	5,527,522	6/18/96	Lauffer et al.	424	9.362	
	36	5,538,945	7/23/96	Pallenberg et al.	514	6	
	*37	5,550,183	8/27/96	Pickart	514	6	
	38	5,554,375	9/10/96	Pickart	424	401	
	39	5,585,466	12/17/96	Carter	530	363	
	*40	5,591,711	1/7/97	Koyama et al.	514	6	
	41	5,624,900	4/29/97	Suda et al.	514	13	
	42	- 5,628,982	5/13/97	Lauffer et al.	424	9.363	
()	43	5,631,172	5/20/97	Johnson	436	543	
N/X	44	_ 5,637,311	6/10/97	Pallenberg	424	434	
	45	5,637,578	6/10/97	Riley et al.	514	186	
	46	5,639,624	6/17/97	Wagner et al.	435	7.92	
	47	5,650,134	7/22/97	Albert et al.	424	1.69	
	48	5,654,160	8/5/97	Johnson	435	7.9	
	49	5,663,301	9/2/97	Johnson	530	363	(
	50	5,670,627	9/23/97	Johnson	530	388.9	
2/2	51	5,670,645	9/23/97	Johnson	546	141	
1	52	5,683,907	11/4/97	Johnson	436	518	
	53	5,710,172	1/20/98	Kukreja et al.	514	400	
	54	5,739,395	4/14/98	Bergeron, Jr.	562	565	•
	55	5,770,178	6/23/98	Itaya et al.	424	1.69	
	56	5,776,892	7/7/98	Counts et al.	514	11	
	57	5,780,594	7/14/98	Carter	530	363	
1	58	5,785,948	7/28/98	Itaya et al.	424	1.69	
A	59	5,786,335	7/28/98	Cody et al.	514	17	
1 2 4 5 2	60	5,807,535	9/15/98	Smith et al.	424	1.65	
XXA	61	5,858,993	1/12/99	Pickart	514	60	
XX	62	5,874,573_	2/23/99	Winchell et al.	540	465	

**EXAMINER** 

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-14 TRADEMIN

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO. 4172-3	SERIAL NO. 09/678,202	
APPLICANT BAR-OR et al.		
T		

**GROUP ART** 

$\mathcal{A}$	63	5,888,522	3/30/99	Pickart	424	401	
1	64	5,906,996	5/25/99	Murphy	514	674	
1/	65	5,922,761	7/13/99	Lai	514	476	
01	66	- 5,994,339	11/30/99	Crapo et al.	514	185	
	67	6,017,888	1/25/00	Pallenberg et al.	514	19	
	68	6,004,953	12/21/99	Volpin et al.	514	185	
	69	6,022,879	2/8/00	Crow et al.	514	319	
$\sqrt{\mathbf{v}_{\alpha}}$	70	6,083,758	7/4/00	Imperiali et al.	436	73	
XIX	71	6,084,093	7/4/00	Riley et al.	540	465	

**FILING DATE** 

September 29, 2000

### FOREIGN PATENT DOCUMENTS

						SUB	TRANSL	ATION
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	NO
XX	72	WÓ 91/17760	11/1991	PCT				
	73	<ul> <li>WO 93/23425</li> </ul>	11/1993	PCT				
	74	WO 94/26295	11/1994	PCT				
V	75	WO 97/44313	11/1997	PCT				
	76	WO 97/49409	12/1997	PCT				
XX	77	WO 98/54138	/ 12/1998	PCT	_			
	78	WÓ 99/39706	8/1999	PCT				
	*79	WÓ 00/20840	4/2000	PCT	_			
	*80	WO 00/20454	4/2000	PCT				
\/	81	. WO 00/36136	6/2000	PCT				
07	82	327263	1/1989	EPO	-			
242	83	719790	12/1995	EPO	)			

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

$\nearrow$		84	Adman, Advances in Protein Chemistry, 42:145-197 (1991)	
ZZI		*85	Aitken, Mol. Biotech., 12:241-253 (1999)	
X,		86	Ames et al., Proc. Natl. Acad. Sci. USA, 90:7915-7922 (1993)	
	$\overline{}$			

EXAMINER XX

DATE CONSIDERED

0/6/03

\*EXAMINER: Initial if reference considered, who ther or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTOP 1449 U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4172-3	SERIAL NO. 09/678,202
APPLICANT BAR-OR et al.	
<del></del>	

**GROUP ART** 


	)		
X	8	7	Atanasiu et al., Mol. Cell. Biochem., 189:127-135 (1998)
,	8	8	Atwood et al., J. Biol. Chem., 273(21):12817-12826 (1998) -
	8	9	Aust, Bibl. Nutr. Dieta. Basel, Karger, No. 43, pp. 266-277 (1989)
	*9	90	Bal et al., Chem. Res. Toxicol., 10(8):906-914 (1997)
	*9	91	Bal et al., Chem. Res. Toxicol., 10:915-921 (1997)
	9	2	Beaulieu et al., J. Cerebral Blood Flow and Metabolism, 18:1022-1031 (1998)
1/	9	3	Belayev et al., J. Neurotrauma, 16(6):445-453 (1999)
	9	4	Bossu et al., Inorganic Chemistry, 17(4):1034-1042 (1978)
XX	9	5	Bourdon et al., FASEB J., 13:233-244 (1999)
1	9	6	Buranaprapuk et al., Biochim Biophys Acta, 1387:309-316 (1998)
	9	7	Calabrese et al., <i>Biochem. J.</i> , <b>238</b> :291-295 (1986)
	9	8	Canters et al., FEBS, 325(1,2):39-48 (1993)
	9	9	Chakrabarti, Protein Engineering, 4(1):57-63 (1990)
	*10	00	Chan et al., Eur. J. Biochem., 227:524-528 (1995)
	*10	01	Cotelle et al., J. Inorganic Biochemistry, 46:7-15 (1992)
V	10	02	Das et al., Methods in Enzymology, 233:601-611 (1994)
1	10	03	Davies, J. Biol. Chem., 262(20):9895-9901 (1987)
XX	10	04	Davies, J. Biol. Chem., 262(20):9902-9907 (1987)
1	10	05	Davies, J. Biol. Chem., 262(20):9908-9913 (1987)
	10	06	Davies, J. Biol. Chem., 262(20):9914-9920 (1987)
	10	07	Dunphy et al., Am. J. Physiol., 276:H1591-H1598 (1999)
	10	08	Farkas et al., J. Chem. Soc. Dalton Trans., pp. 611-614 (1984)
	10	09	Florence, Australian and New Zealand J. Opthamol., 23(1):3-7 (1995)
V	<i>p</i> 11	10	Fu et al., Biochem. J., 333:519-525 (1998)
XX	11	11	Gutteridge et al., Biochim. Biophys. Acta, 759:38-41 (1983)
	11	12	Halliwell and Gutteridge, "Free Radicals in Biology and Medicine" pp. 1-21 (2nd ed. Clarendon Press - Oxford 1989)
	11	13	Halliwell et al., Arch. Biochem. Biophys., 280(1):1-8 (1990)
	11	14	Halliwell et al., Arch. Biochem. Biophys., 246(2):501-514 (1986)
	, *1	15	Harford et al., Acc. Chem. Res., 30:123-130 (1997)
Ψ	11	16	He et al., Biochemistry, 38:9704-9711 (1999)
	) 11	17	Hirose et al., Biochim. Biophys. Acta, 1296:103-111 (1996)
avar	1 11	18	Hisatomi et al., <i>Transplantation</i> , <b>52(4)</b> :754-755 (1991)
7	11	19	Huh et al., Brain Res., 804:105-113 (1998)

**FILING DATE** 

September 29, 2000

			<u> </u>					•
EXAMINER	Lavid	Lytto		DATE CONSIDERED	10/	6/	03	
						-		

\*EXAMINER: Initial if reference considered, who ther or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

# U.S. DER TIMENT OF COMMERCE PATENT/RADE PA

SERIAL NO. 09/678,202

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

**APPLICANT** BAR-OR et al.

ATTY. DOCKET NO.

4172-3

FILING DATE September 29, 2000 **GROUP ART** 

		•
XX.	120	Keller et al., Chem. Res. Toxicol., 6:430-433 (1993)
	121	Kerr et al., Heart Lung, 25:200-9 (1996)
	122	Khan et al., Biochem. Pharmacol., 43(9):1963-1967 (1992)
	123	Knight, Ann. Clin. Lab. Sci., 25(2):111-121 (1995)
N <sub>a</sub>	124	Koch et al., Chemistry & Biology, 4:549-560 (1997)
	125	Kowalik-Jankowska et al., "Copper(II) Complexes with Oligopeptides Containing Serine, Methionine or Phenylalanine Residues" pp. 1184-1197 (9/24/1992)
	*126	Kowalik-Jankowska et al., J. Inorg. Biochem., 66:193-196 (1997)
	*127	Kruck et al., Can. J. Chem., 54:1300-1308 (1976)
	*128	Lappin et al., Inorganic Chemistry, 17(6):1630-1634 (1978)
	*129	Laussac et al., Biochemistry, 23:2832-2838 (1984)
	130	Leeuwenburgh et al., Am J. Physiol., 274:R453-R461 (1998)
	131	Legrand et al., Biochimie, 70:1185-1195 (1988)
V	132	Little et al., Neurosurgery, 9(5):552-558 (1981)
00	133	Loban et al., Clinical Science, 93:445-451 (1997)
#K	134	Machonkin et al., <i>Biochemistry</i> , <b>37</b> :9570-9578 (1998)
	135	Malins et al., <i>Proc. Natl. Acad. Sci USA</i> , <b>93</b> :2557-2565 (1996)
	136	Malmström et al., Curr Op. Chem. Biol., 2:286-292 (1998)
	137	Manso, Rev. Port. Cardiol., 11(11):997-999 (1992)
	138	Maret et al., Methods in Enzymology, 226:52-71 (1993)
	*139	Marx et al., Biochem. J., 236:397-400 (1985)
	140	Masuoka et al., <i>J. Biol. Chem.</i> , <b>268</b> (29):21533-21537 (1993) —
	141	McGuirl et al., Curr. Op. Chem. Biol., 3:138-144 (1999)
Λ.	142	Miller et al., Arch. Biochem. Biophys., 295(2):240-246 (1992)
	*143	Mlynarz et al., "α-Hydroxymethylserine (HMS) Makes HMS-HMS-His the Most Efficient Tripeptide Ligand for Cu²+ lons" (1998) Speciation 98:Abstract
ſ	144	Musci et al., Arch. Biochem. Biophys., 306(1):111-118 (1993)
	145	Praticò et al., J. Clin. Invest., 100(8):2028-2034 (1997)
	*146	Predki et al., Biochem. J., 287:211-215 (1992) —
	*147	Quinlan et al., J. Pharm. Sci., 81(7):611-614 (1992)
	148	Rao et al., Ann. Thorac. Surg., 52:908-12 (1991)
	149	Regan, Annu. Rev. Biophys. Biomol. Struct., 22:257-81 (1993)
LP	150	Regan, TIBS 20, pp. 280-285 (1995)
XX.	151	Remmers et al., <i>Brain Research</i> , <b>827</b> :237-242 (1999)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO TRADETENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4172-3	SERIAL NO. 09/678,202		
APPLICANT BAR-OR et al.			
FILING DATE	GROUP ART		

September 29, 2000

$\triangle \ell$		
X	152	Rosenthal et al., Free Radical Biology & Medicine, 12:29-33 (1992)
	153	Röth, Acta Chirurgica Hungarica, <b>36</b> (1-4):302-305 (1997)
	154	Rupp et al., Biochim. Biophys. Acta., 446:151-165 (1976)
	155	Russell et al., Free Radical Biology & Medicine, 25(2):153-159 (1998)
	156	Rylkov et al., <i>Eur. J. Biochem.</i> , <b>197</b> :185-189 (1991)
$\bigcap_{i}$	*157	Sadler et al., Eur. J. Biochem., 220:193-200 (1994)
198	158	Salvemini et al., <i>Science</i> , <b>286</b> :304-306 (1999)
	159	Si et al., GLIA, 21:413-418 (1997)
	160	Smith et al., J. Histochem. Cytochem., 46:731-735 (1998)
	*161	Spencer et al., J. Cardiovasc. Pharmacol., 32(3):343-348 (1998)
$\bigcap_{\alpha} V_{\alpha}$	162	Stohs, J. Basic & Clin. Physiol. Pharmacol., 6(3-4):205-229 (1995)
XX	163	Süzer et al., <i>Pharmacol. Res.</i> , <b>37</b> (2):97-101 (1998)
	*164	Ueda et al., J. Inorgan. Biochem., 55:123-130 (1994)
	*165	Ueda et al., Chem. Pharm. Bull., <b>43</b> (2):359-361 (1995)
	*166	Ueda et al., Free Radical Biology & Medicine, 18(5):929-933 (1995) .
	167	Whittal et al., Protein Science, 9:332-343 (2000)
	168	Wolff et al., TIBS 11, pp. 27-31 (1986)
	169	Wysocki et al., Coronary Artery Disease, 4:645-647 (1993)
MX	170	Yamada et al., Biochem. Mol. Biol. Intl, 46(4):733-738 (1998)

EXAMINER

DATE CONSIDERED

10/6/03

\*EXAMINER: Initial if reference considered, who ther or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.